Oncosil Medical Ltd has released a press release.
Appendix 4E and Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Response to ASX Price Query
- Update - CE Marking Application
- CE Marking Update
- PanCo Study Interim Analysis
- R&D Refund - 2018 Financial Year
Later from OncoSil Medical
- Receipt of $3.8M R&D Tax Incentive
- OncoSil AGM CEO Presentation
- Positive CE Mark Status Report
- CE Mark Update
- FDA Grants Breakthrough Device Designation
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical